Advanced Filters
noise

Tokyo and Other Japanese City, Japan Clinical Trials

A listing of Tokyo and Other Japanese City, Japan clinical trials actively recruiting patients volunteers.

Found 64,712 clinical trials
T Tao Wang, doctorial

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

This clinical trial studies the efficacy and safety of selinexor combined with HAD or CAG regimen in the treatment of relapsed or refractory acute myeloid leukemia

18 - 60 years of age All Phase 3
M Miao Chen

Sirolimus in the Treatment of Refractory/Relapsed wAIHA

Autoimmune hemolytic anemia (AIHA) is a rare and heterogeneous disorder characterized by the destruction of red blood cells through warm or cold antibodies. Glucocorticoid (combined with rituximab) is the first-line treatment. However, the recurrence rate is very high and some patients may not respond to steroids. Second-line therapies include cyclosporine …

18 - 90 years of age All Phase N/A
W Wenzhe Wu, Master

Efficacy on Walking Ability of Electroacupuncture Therapy in Elderly Patients With Sarcopenia

Introduction: The efficacy of existing therapies for the treatment of sarcopenia is still not satisfactory. Therefore, this randomized controlled, assessor-blinded study was designed to investigate the efficacy and safety of electroacupuncture(EA) therapy in elderly patients with sarcopenia. Methods and analysis: This randomized controlled trial will enroll 120 elderly patients with …

60 - 95 years of age All Phase N/A
K Kim Ross

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

This is an open-label phase 1 study with an escalation part and an expansion part.

18 - 75 years of age All Phase 1
T Tara Churney, MPH

The Role of Laryngopharyngeal Reflux in IPF

The primary objective of this study is to show that the Supraglottic Index (SGI) is an easily-collected index that accurately identifies the presence and severity of laryngopharyngeal reflux (LPF) in idiopathic pulmonary fibrosis (IPF).

40 - 95 years of age All Phase N/A
R Reid W Merryman, MD

Epcoritamab and Rituximab for First-line Follicular Lymphoma

The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: Rituximab (a type …

18 years of age All Phase 2

Time of Oxytocin Initiation at 2nd Stage of Labor and Adverse Outcomes

Early oxytocin administration at the 2nd stage of labor is associated with a higher rate of vaginal delivery, shorter second stage duration, and fewer adverse maternal and neonatal outcomes.

18 years of age Female Phase N/A
O Oscar Ronzio, DHSc PT

Efficacy of Percutaneous Electrolysis in the Treatment of Achilles Tendinopathy

Achilles tendinopathy (AT) is one of the most reported myotendinous pathologies due to overuse in the literature. In the general adult population, its incidence is 2.35 cases per 1,000 patients, with no difference between men and women. The international literature reports that up to 29% of patients fail with conservative …

18 - 65 years of age All Phase N/A
S Study Coordinator

Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae

An experimental hookworm infection model is being developed to provide early proof-of-concept that a hookworm vaccine targeting the blood-feeding pathway of adult hookworms is feasible and efficacious. The proposed model consists of vaccinating healthy, hookworm-naïve adults with a candidate hookworm vaccine, followed by challenging them with the investigational product, Necator …

18 - 45 years of age All Phase 1
E Eduard A. Ponomarev, MD, PhD

Thrombolysis With Recombinant Non-immunogenic Staphylokinase vs Surgery in Patients With Acute Limb Ischemia FORAT Trial

Objective: to evaluate the efficacy and safety of intra-arterial intrathrombus administration of the recombinant non-immunogenic staphylokinase (Fortelyzin®) in patients with acute limb ischemia (ALI) vs surgery.

18 years of age All Phase 3

Simplify language using AI